Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
The entire integration and transition of the brands is expected to be completed by March 2022
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The service has already been initiated in Maharashtra but being net-based it is easily available for patients all across the country
It will open new frontier for south-to-south collaboration and innovation transfer
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Subscribe To Our Newsletter & Stay Updated
